Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Zydus Pharmaceuticals Usa, Inc v. Eli Lilly and Company

August 1, 2011

ZYDUS PHARMACEUTICALS USA, INC.,
PLAINTIFF,
v.
ELI LILLY AND COMPANY, DEFENDANT.



The opinion of the court was delivered by: Hon. Dennis M. Cavanaugh

NOT FOR PUBLICATION

OPINION

DENNIS M. CAVANAUGH, U.S.D.J.:

This matter comes before the Court upon the motion of Plaintiff Zydus Pharmaceuticals USA, Inc. ("Zydus") for Judgment on the Pleadings pursuant to Federal Rule of Civil Procedure 12(c). No oral argument was heard under Rule 78. For the reasons stated below, Plaintiff's motion is DENIED.

I. BACKGROUND*fn1

This matter is related to an action currently pending appeal before the Federal Circuit. In Eli Lilly v. Actavis Elizabeth LLC, No. 07-3770 (DMC) (the "Actavis Action"), Eli Lilly and Company ("Lilly"), as plaintiff, alleged that Zydus and a number of other generic drug companies infringed on Lilly's United States Patent No. 5,658,590 ("the '590 Patent") by filing Abbreviated New Drug Applications ("ANDA") seeking to manufacture, market, and/or sell generic versions of Lilly's atomoxetine hydrochloride product marketed under the brand name Stratera.® In December 2007, Zydus and Lilly agreed to a consent judgment (the "Consent Judgment") disposing of Lilly's claims against Zydus in the Actavis Action. The Consent Judgment stipulated that:

Zydus, its officers, agents, servants, employees and attorneys, and those persons in active concert or participation with them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell or selling within the United States, or importing into the United States, any of the generic atomoxetine hydrochloride products defined by ANDA 79-017 during the life of the '590 patent, including any extensions (including under 35 U.S.C. § 156 and including periods of regulatory exclusivity associated with the patent, such as pediatric exclusivity under 21 U.S.C. § 355a), absent authorization by Lilly.

Boyle Decl., Ex. C at 3 (emphasis added).

Five defendants remained in the Actavis Action through a bench trial in August 2010. Following trial, this Court entered judgment against Lilly finding, in pertinent part, that the '590 Patent was invalid for lack of enablement/utility under 35 U.S.C. § 112. This Court also entered a 14-day injunction to allow the Federal Circuit time to determine whether an interim injunction pending resolution of the appeal was warranted. Lilly immediately appealed the invalidity determination and the Federal Circuit ordered that the injunction entered by this Court be continued through the duration of appellate review.

To ensure that Zydus was bound by the Federal Circuit's injunction, Lilly moved to amend the official case caption so as to add Zydus as a named defendant-appellee. That motion was denied. Lilly then moved this Court to confirm that Zydus was bound by this Court's initial 14-day injunction. This Court denied Lilly's motion, finding that it no longer retained jurisdiction over the Actavis Action.

Zydus subsequently filed the present action for Declaratory Judgment on October 27, 2010, seeking a judgment from this Court that "Zydus may proceed, in its sole discretion and without any bar imposed by the Federal Circuit's Injunction and/or Consent Judgment, to immediately manufacture, use, offer to sell and sell within the United States, or import into the United States, generic atomoxetine hydrochloride products, including those defined by Zydus's ANDA 79-017." Compl. at 8. Within days, Lilly responded by filing a motion for a temporary restraining order and preliminary injunction against Zydus, seeking to prevent an at-risk generic launch of its product. That motion was withdrawn after the parties stipulated that Zydus would not market or sell its generic atomoxetine products until this Court resolves the present matter, or the Federal Circuit affirms the invalidity of all claims of the '590 patent on appeal, whichever comes first.

II.STANDARDOFREVIEW

Federal Rule of Civil Procedure 12(c) allows a party to move for judgment on the pleadings after the pleadings are closed. To succeed on such a motion, the moving party must show that "no material issue of fact remains to be resolved and that [the moving party] is entitled to judgment as a matter of law." Rosenau v. Unifund Corp., 538 F.3d 218, 221 (3d Cir. 2008) (quoting Jablonski v. Pan Am. World Airways, Inc., 863 F.2d 289, 290-91 (3d Cir. 1988) (internal quotation marks omitted)).

As in a motion to dismiss for failure to state a claim, in deciding a motion for judgment on the pleadings, all allegations in the complaint must be taken as true and viewed in the light most favorable to the plaintiff. See Turbe v. Gov't of Virgin Islands, 938 F.2d 427, 428 (3d Cir. 1991). Moreover, a court may consider only the complaint, exhibits attached to the complaint, matters of public record, and undisputedly authentic documents if the plaintiff's claims are ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.